Dillard's vs Five Below
DDS and FIVE side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DDS and FIVE compare
Five Below is the larger company, worth 1.3 times as much as Dillard's ($13.3B against $10.3B).
Five Below grew revenue faster over the last twelve months (25.6% versus 0.21% for Dillard's).
Five Below keeps more of each dollar of sales as profit, with a net margin of 11.7% compared with 10.3% at Dillard's.
Dillard's pays a dividend yielding 0.18%; Five Below does not pay one.
Five Below scores higher on the StockData Score (21 against 11 for Dillard's), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DDS | FIVE |
|---|---|---|
| Size and price | ||
| Market cap | $10.3B | $13.3B |
| Share price | $660.84 | $240.96 |
| Change, 1 year | 8.6% | 49.1% |
| Change, 5 years | 118% | 14.7% |
| Beta (5Y) | 1.30 | 1.35 |
| Employees | 29K | – |
| StockData Score | ||
| Total score | 11 | 21 (better) |
| Valuation score | 1 | 3 (better) |
| Growth score | 1 | 6 (better) |
| Performance score | 3 | 6 (better) |
| Health score | 2 | 6 (better) |
| Dividend score | 4 (better) | 0 |
| Valuation | ||
| P/E | – | 21.6× |
| P/S | 1.6× (better) | 2.5× |
| P/B | 4.9× (better) | 5.4× |
| EV/EBITDA | 9.0× (better) | 12.3× |
| P/FCF | 16.3× (better) | 22.1× |
| PEG | – | 1.91 |
| FCF yield | 6.2% (better) | 4.5% |
| Fair value | $724.85 | $290.42 |
| Margin of safety | 8.8% | 17.0% (better) |
| Growth | ||
| Revenue growth (TTM) | 0.21% | 25.6% (better) |
| Revenue growth, 5Y average | 8.2% | 19.4% (better) |
| Net income growth (TTM) | 18.4% | 127% (better) |
| EPS growth (TTM) | – | 126% |
| EPS growth, 5Y average | – | 24.1% |
| Profitability | ||
| Gross margin | 39.8% | 40.3% (better) |
| Operating margin | – | 14.7% |
| Net margin | 10.3% | 11.7% (better) |
| FCF margin | 9.6% | 11.3% (better) |
| Return on equity | 33.8% (better) | 28.3% |
| Return on invested capital | – | 46.9% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Current ratio | 3.03 (better) | 2.22 |
| Altman Z-score | 8.62 (better) | 5.24 |
| Piotroski F-score | 6 | 8 (better) |
| Dividends and buybacks | ||
| Dividend yield | 0.18% | – |
| Payout ratio | 71.3% | – |
| Years of dividend growth | 12 | – |
| Dividend growth, 5Y average | 120% | – |
| Shareholder yield | 0.18% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 53.6% | 101% |
| Held by insiders | 48.6% | 1.9% |
| Insider net buying, 12 months | −$244K (better) | −$23.7M |
| Superinvestors holding | – | 2 |
| Short interest, % of float | – | 5.4% |
Go deeper
- DDS stock overview
- DDS income statement
- DDS valuation and score
- FIVE stock overview
- FIVE income statement
- FIVE valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.